Sign In
Buy DGX
$193.67
+0.510 (+0.264%)
At Close: Jun 03, 2026
DGX Stock Rises on Q3 Earnings and Revenue Beat, 2024 Sales View Up
10:40am, Tuesday, 22'nd Oct 2024
Quest Diagnostics' third-quarter 2024 performance reflects impressive DIS business growth and the benefits of new acquisitions.
Quest Diagnostics (DGX) Beats Q3 Earnings and Revenue Estimates
09:00am, Tuesday, 22'nd Oct 2024
Quest Diagnostics (DGX) came out with quarterly earnings of $2.30 per share, beating the Zacks Consensus Estimate of $2.26 per share. This compares to earnings of $2.22 per share a year ago.
Quest Diagnostics beats quarterly results estimates on diagnostic test demand
08:05am, Tuesday, 22'nd Oct 2024
Laboratory operator Quest Diagnostics beat Wall Street estimates for third-quarter profit and revenue on Tuesday, helped by robust demand for its diagnostic tests.
Quest Diagnostics Reports Third Quarter 2024 Financial Results; Updates Guidance for Full Year 2024
06:45am, Tuesday, 22'nd Oct 2024
Third quarter revenues of $2.49 billion, up 8.5% from 2023 Third quarter reported diluted earnings per share ("EPS") of $1.99, up 1.5% from 2023; and adjusted diluted EPS of $2.30, up 3.6% from 2023 F
Are Investors Undervaluing Quest Diagnostics (DGX) Right Now?
10:45am, Wednesday, 16'th Oct 2024
Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest
Quest Diagnostics (DGX) Earnings Expected to Grow: What to Know Ahead of Next Week's Release
11:06am, Tuesday, 15'th Oct 2024
Quest Diagnostics (DGX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
First-of-its-kind service empowers discreet and more convenient access to testing and treatment for vaginitis and similar genital tract infections such as chlamydia, gonorrhea, trichomoniasis and Myco
Quest Diagnostics: The Better Half Of An Emerging Healthcare Duopoly
03:28am, Tuesday, 15'th Oct 2024
Quest Diagnostics is a dominant player in the growing medical testing industry, offering consistent earnings and dividend growth with lower volatility. DGX benefits from secular tailwinds like aging p
DGX Gears Up for Q3 Earnings: What Lies Ahead for the Stock?
10:25am, Monday, 14'th Oct 2024
Quest Diagnostics is expected to deliver robust base business growth in the third quarter of 2024.
Quest Diagnostics Completes Acquisition of Lab Assets from OhioHealth
08:50am, Monday, 14'th Oct 2024
Goal to broaden access to cost-effective and innovative laboratory services in Ohio SECAUCUS, N.J. , Oct. 14, 2024 /PRNewswire/ -- Quest Diagnostics (NYSE: DGX), a leader in diagnostic information ser
Should You Add Quest Diagnostics Stock to Your Portfolio Right Now?
08:45am, Wednesday, 09'th Oct 2024
DGX's strength in Advanced Diagnostics and robust base business volumes are encouraging.
Is Quest Diagnostics (DGX) Stock Undervalued Right Now?
10:46am, Monday, 30'th Sep 2024
Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest
Quest Diagnostics to Release Third Quarter 2024 Financial Results on October 22, 2024
11:24am, Wednesday, 25'th Sep 2024
SECAUCUS, N.J. , Sept. 25, 2024 /PRNewswire/ -- Quest Diagnostics Incorporated (NYSE: DGX), a leader in diagnostic information services, announced that it will report third quarter 2024 financial resu
Quest Diagnostics Stock Gains From New Offerings, Customer Wins
09:26am, Wednesday, 25'th Sep 2024
A key driver in Brain Health growth is Quest Diagnostics' Alzheimer's disease portfolio, featuring the AD-Detect blood testing services and the CSF tests.
Here's Why Quest Diagnostics (DGX) is a Strong Value Stock
10:46am, Tuesday, 24'th Sep 2024
The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.
